Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 02, 2015 11:36 AM ET


Company Overview of CROMA-PHARMA GmbH

Company Overview

CROMA-PHARMA GmbH, a pharmaceutical company, develops, manufactures, and distributes products in aesthetic dermatology field. The company offers injectable gels based on hyaluronic acid of non-animal origin for non-surgical beauty treatments and aesthetic indications, such as the correction of facial wrinkles and folds, lines, cutaneous depressions, facial contours, and the creation of volume. It also offers skincare products, which include hyaluron based day and night creams, serums, body lotions, face masks, moisturizing gels, anti-ageing serums, and essence recovery products; and lift products, such as a line of sutures for lifting and revitalizing effect, and a line of lifting threads ma...

Industriezeile 6

Leobendorf,  2100


Founded in 1976


43 22 62 684 68 0


43 22 62 684 68 165

Key Executives for CROMA-PHARMA GmbH

Chief Executive Officer, Managing Director and Member of Management Board
Managing Director and Member of Management Board
Managing Director and Member of Management Board
Compensation as of Fiscal Year 2015.

CROMA-PHARMA GmbH Key Developments

Croma-Pharma Mulls IPO

Croma-Pharma Gmbh is considering an initial public offering (IPO) in 3-5 years, according to WirtschaftsBlatt which cited one of the owners, Andreas Prinz.

Croma-Pharma Gmbh Announces the Signing of Distribution Agreement with Hugel Inc

Croma-Pharma Gmbh announced the signing of a 10 year distribution agreement with Hugel Inc. CROMA-PHARMA will become the exclusive Distribution Partner and will be responsible for conducting the required clinical trials and studies. CROMA-PHARMA expects to invest an estimated two-digit million Euro amount for conducting these studies. Following the final approval of FDA, EMA and other authorities, CROMA-PHARMA will then market the new products in Europe, North America and Oceania markets. CROMA-PHARMA will promote the new products under their own brand. Products shall enter the markets in 2018. Forecast of sales until 2021 estimate returns of more than EUR 100 million in this dynamically growing market.

Similar Private Companies By Industry

Company Name Region
Nycomed Austria Gmbh Europe
Novartis Austria GmbH Europe
SL Pharma Holding GmbH Europe
Biomay Produktions- und Handels AG Europe
Actavis GmbH Europe

Recent Private Companies Transactions

September 23, 2014
CROMA-PHARMA GmbH, Ophthalmology and Orthopaedics Divisions

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CROMA-PHARMA GmbH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at